InMed Pharmaceuticals Inc. (INM) Form 8-K — Nov 10, 2026
$INMForm 8-KItems 1.01, 2.01, 2.02, 3.02, 3.03, 5.01, 5.02, 5.03, 5.05, 5.06, 9.01Filed Nov 10, 2026, 4:45 PM ET0001193125-26-455640Original filing
InMed Pharmaceuticals completed its reverse merger with privately held Mentari Therapeutics on November 6, 2026, and the combined company — renamed Mentari Therapeutics, Inc. — began trading on Nasdaq under the new ticker MTRI on November 9, 2026. The deal was transformative and heavily dilutive to legacy InMed holders: after a 1-for-10 reverse split, a redomestication from Canada to Nevada, and a ~$490.0 million pre-closing PIPE, former InMed shareholders retain only about 1% of the company on a fully diluted basis, with Mentari holders owning ~99%.
Key figures
- Gross Proceeds
- 490000000
- Shares Offered
- 215042178
- New ticker
- MTRI
- Exchange ratio
- 0.20065 shares of Company Common Stock per Mentari share
- Prefunded warrants
- 7317328
- Reverse split ratio
- 1:10
- Mentari valuation in financing
- 125000000
- Shares outstanding post merger
- 52813914
- Cvr business development budget
- 100000
- Fully diluted shares post merger
- 58295136
- Inmed holders ownership post merger
- ~1.0%
- Mentari holders ownership post merger
- ~99.0%
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.